GATA binding protein 3 (GATA3) as a marker for metaplastic spindle cell carcinoma of the breast

被引:7
|
作者
Jin, Cao [1 ]
Hacking, Sean [1 ]
Sajjan, Sujata [1 ]
Kamanda, Sonia [1 ]
Bhuiya, Tawfiqul [1 ]
Nasim, Mansoor [1 ]
机构
[1] Donald & Barbara Zucker Sch Med Northwell, Dept Pathol & Lab Med, Hempstead, NY 11549 USA
关键词
Metaplastic breast carcinomas; Spindle cell lesions; GATA3; Cytokeratin; Marker; PHYLLODES TUMOR; P63; EXPRESSION; FIBROMATOSIS; DIFFERENTIATION; DIAGNOSIS; LESIONS; CANCER;
D O I
10.1016/j.prp.2021.153413
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Spindle cell lesions of the breast comprise a diverse set of tumors; harboring significant histological and immunohistochemical (IHC) overlap. Accurate diagnosis and classification of spindle cell lesions in the breast remains challenging, especially in core biopsies. In the current study, we evaluated a spectrum of spindle cell lesion of the breast with a panel of IHC antibodies in an effort to differentiate metaplastic spindle cell carcinoma from its benign and malignant mimickers. Our study included 92 patients who underwent breast core biopsies or breast resections at Northwell Health who were diagnosed with benign and malignant tumor/tumor-like spindle cell lesions. Tumors subtypes in this the study included: angiosarcoma, nodular fasciitis, fibromatosis, myofibroblastoma, phyllodes tumors (benign, borderline and malignant), primary sarcomas and metaplastic spindle cell carcinoma. Our biomarker panel included high molecular weight keratin (HMWK), CAM5.2, AE1/AE3, p63, CD34 and GATA3. GATA3 expression was significantly higher in metaplastic carcinomas (88.9 % vs 4.1 %, p < 0.001), when compared to other spindle cell lesions. The sensitivity and specificity for detecting metaplastic carcinomas reached 84.2 % and 97.3 %, respectively. Regarding cytokeratin panels, none of the three individual markers were as sensitive or specific for metaplastic breast carcinoma. GATA3 is the most specific and sensitive marker forfor the identification of metaplastic spindle cell carcinoma of the breast.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] GATA3 as a potential marker for breast carcinoma
    Kjaer, Dorte
    Brugmann, Anja
    Nielsen, Soren
    Jensen, Vibeke
    APMIS, 2014, 122 : 13 - 13
  • [2] GATA binding protein 3 (GATA-3) as a new prognostic marker in breast cancer
    Kim, L.
    Kang, H.
    Lee, Y.
    Cho, Y.
    EJC SUPPLEMENTS, 2010, 8 (03): : 115 - 115
  • [3] GATA3: A promising marker for metastatic breast carcinoma in serous effusion specimens
    Shield, Paul W.
    Papadimos, David J.
    Walsh, Michael D.
    CANCER CYTOPATHOLOGY, 2014, 122 (04) : 307 - 312
  • [4] GATA3 mutations in breast cancer
    Takaku, Motoki
    Adomas, Aleksandra
    Grimm, Sara A.
    Takashi, Shimbo
    Wade, Paul A.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] GATA3 as a New Marker of Gonadotroph Adenomas
    Bidot, Samuel
    Goodman, Abigail
    Lowder, Lindsey
    Vega, Jose Velazquez
    Hunter, Stephen
    Neill, Stewart
    Schniederjan, Matthew
    MODERN PATHOLOGY, 2019, 32
  • [6] GATA3 as a New Marker of Gonadotroph Adenomas
    Bidot, Samuel
    Goodman, Abigail
    Lowder, Lindsey
    Vega, Jose Velazquez
    Hunter, Stephen
    Neill, Stewart
    Schniederjan, Matthew
    LABORATORY INVESTIGATION, 2019, 99
  • [7] GATA3 Is a Useful Marker to Identify Breast Origin in FNA Samples
    Ghorab, Z.
    Hosseini, N.
    Han, G.
    Dube, V.
    Wong, J.
    Nofech-Mozes, S.
    LABORATORY INVESTIGATION, 2014, 94 : 103A - 103A
  • [8] GATA3 Is a Useful Marker to Identify Breast Origin in FNA Samples
    Ghorab, Z.
    Hosseini, N.
    Han, G.
    Dube, V.
    Wong, J.
    Nofech-Mozes, S.
    MODERN PATHOLOGY, 2014, 27 : 103A - 103A
  • [9] Expression of TRPS1, SOX10 and GATA3 in Different Subtypes of Metaplastic Breast Carcinoma
    Yoon, Esther
    Li, Zaibo
    Huo, Lei
    Gan, Qiong
    Middleton, Lavinia
    Sahin, Aysegul
    Ding, Qingqing
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 214 - 215
  • [10] Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer
    Cohen, Helit
    Ben-Hamo, Rotem
    Gidoni, Moriah
    Yitzhaki, Ilana
    Kozol, Renana
    Zilberberg, Alona
    Efroni, Sol
    BREAST CANCER RESEARCH, 2014, 16 (06):